Oral · GLP-1 agonist
HDM1002
13 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
13
Active
11
Recruiting
6
Completed
1
Sites
37
Countries
1
Endpoints
144
Composite endpoints
25
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
8
Phase 2
2
Phase 3
3
Trials by status
Not yet recruiting
5
Recruiting
6
Completed
1
Unknown
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
88
Glycemic / diabetes
26
Weight & body composition
20
Cardiometabolic biomarkers
8
Patient-reported / QoL
2
Most-measured metrics
Top 20 metrics across this asset's endpoints
AUC₀–∞Safety/PK
23
Treatment-emergent AEs (any)Safety/PK
10
CmaxSafety/PK
10
TmaxSafety/PK
8
Half-lifeSafety/PK
7
HbA1c, changeGlycemic
6
Fasting glucose, changeGlycemic
4
Body weight, % changeWeight
4
≥10% weight-loss respondersWeight
4
HbA1c <7.0% achievementGlycemic
3
HOMA-IR (insulin sensitivity)Glycemic
3
Postprandial glucoseGlycemic
3
Body weight, absolute change (kg)Weight
3
Waist circumference, changeWeight
2
BMI, changeWeight
1
Plasma concentration (steady state)Safety/PK
1
≥5% weight-loss respondersWeight
1
≥15% weight-loss respondersWeight
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
13 of 13